Tag:

Servier

Latest Headlines

Latest Headlines

Cellectis suffers worst day in two years after Pfizer event disappoints investors

Cellectis suffered its worst day in two years on the Paris stock exchange on Monday. The 13% slump began when it became clear that a conference call held by Cellectis, Pfizer and Servier would do little more than clarify the roles of each party in their recently struck CAR-T collaboration.

Servier plots major layoffs in France after R&D setbacks, payer cuts

France's Servier is plotting big cuts in its home country as part of a companywide refocus. The privately held drugmaker plans to lay off 610 workers, mostly in its commercial operations within France, where sales have plummeted by almost half over the past 5 years.

Servier severs a $450M oncology deal with MacroGenics

French drugmaker Servier is walking away from a partnership with MacroGenics worth up to $450 million, handing back the rights to a cancer immunotherapy after getting a glimpse at clinical data.

Servier hands some cancer candidates to Horizon with £50M on the line

French drugmaker Servier has outlicensed some early-stage cancer treatments to Horizon Discovery, holding on to the rights to buy them back if they come through in preclinical development.

Servier bags EU rights to colorectal cancer drug in $130M deal

Servier has continued its push into oncology and search beyond its walls for innovation by striking a $130 million (€115 million) deal with Taiho Pharmaceutical. The fee, which is made up of an upfront payment and near-term milestone, will give Servier the rights to Taiho's treatment for refractory metastatic colorectal cancer.

GeNeuro snags a $455M deal, inks MS drug pact with Servier

Geneva-based GeNeuro, a spinout of the Institut Mérieux, has come up with a licensing deal that will deliver $47 million needed to complete a Phase IIb study of its experimental therapy for multiple sclerosis. And France's Servier gets an option on ex-U.S. and Japanese rights that's tied to a $408 million package of milestones along with a chance to buy an equity stake in the biotech sometime in the next year.

Servier gambling up to $1B-plus on Intarcia's PhIII diabetes drug/device

Just a few weeks after claiming success with a pair of late-stage studies of its prolonged dosing approach to diabetes, Boston-based Intarcia has followed up with a billion dollar-plus sized commercialization deal for ex-U.S. and Japan commercial rights with France's Servier.

Pharmacyclics, Servier call it quits on a cancer drug

Pharmacyclics and Servier are quietly walking away from a 5-year collaboration on a new cancer treatment, leaving the former company to go it alone on mid-stage oral drug with an uncertain future.

Servier and Amgen's cardio drug faces uncertain future after trial flop

Ivabradine, a heart rate-reducing drug from Servier and Amgen, failed to beat placebo in a huge study of patients with coronary artery disease, potentially clouding its future on two continents.

EU's third pay-for-delay action nails Servier, Teva, Mylan and others

European regulators are getting the hang of levying pay-for-delay penalties, rolling up 6 companies in its latest action and fining them more than half a billion dollars in the process.
'